Detalles de la búsqueda
1.
Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial.
Diabetes Obes Metab
; 26(2): 540-547, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37880868
2.
Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X Trial.
J Diabetes Sci Technol
; : 19322968241232709, 2024 Feb 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38420944
3.
Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin.
Diabetes Ther
; 13(7): 1299-1310, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35650350
4.
Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M).
Diabetes Ther
; 13(5): 1053-1071, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35420397
5.
Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin.
Diabetes Ther
; 12(2): 557-568, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33432547
6.
Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial.
Diabetes Technol Ther
; 22(7): 516-526, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32068436
7.
Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1).
Diabetes Technol Ther
; 22(2): 85-95, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31804851
8.
Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study.
Diabetes Technol Ther
; 20(1): 49-58, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29232162
9.
Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump.
J Diabetes Sci Technol
; 12(3): 680-686, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29359575
10.
Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes.
Diabetes Technol Ther
; 20(2): 160-170, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29355435
11.
Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study.
Diabetes Technol Ther
; 19(9): 516-526, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28722480
12.
Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus.
J Pediatr Endocrinol Metab
; 15(4): 369-76, 2002 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-12008682
Resultados
1 -
12
de 12
1
Próxima >
>>